No Commercially Available Oxycodone Suppository in the United States
There is no FDA-approved oxycodone suppository currently available for clinical use in the United States, though historical formulations existed and rectal administration has been studied.
Historical Context and Current Status
The evidence indicates that oxycodone suppositories were previously available in some countries. The 2001 EAPC guidelines mention that "oxycodone...until recently was most often prescribed in low-dose combination products (with a non-opioid) for oral administration or as a rectal suppository" 1. However, this formulation is not listed in current FDA drug labels or contemporary guidelines.
Available Formulations
Current FDA-approved oxycodone formulations include 2:
- Oral tablets (immediate and extended-release)
- Oral solutions/syrups
- Combination products with acetaminophen or ibuprofen
The 2025 NCCN guidelines confirm that oxycodone is available with an oral dose of 15-20 mg but list no parenteral or rectal formulation 3.
Research Evidence on Rectal Administration
A 1992 pharmacokinetic study examined oxycodone suppositories (30 mg) and found 4:
- Bioavailability <50% compared to IV administration
- Mean absorption lag time of 0.76 ± 0.47 hours
- Elimination half-life similar to oral formulations (5.40 ± 1.19 hours)
This demonstrates that rectal administration is pharmacologically feasible but not commercially developed in modern practice.
Clinical Alternatives for Patients Unable to Take Oral Medications
When oral administration is not possible, current guidelines recommend 3:
First-line alternatives:
- Transdermal fentanyl for stable opioid requirements (≥60 mg morphine equivalents/day)
- Subcutaneous or IV morphine/hydromorphone for acute needs
- Concentrated oral morphine solution (20 mg/mL) for sublingual administration
Important caveat: Morphine and hydromorphone suppositories ARE available and represent the standard rectal opioid option when needed 5.
Bottom Line
If you need rectal opioid administration, use morphine or hydromorphone suppositories, which are commercially available and guideline-supported. Oxycodone suppositories are not part of the current therapeutic armamentarium in the United States.